MedTrace Logo

A Study of a Personalized Neoantigen Cancer Vaccine

NCT03639714 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-09-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.

Conditions

Interventions

BIOLOGICAL

GRT-C901

a patient-specific neoantigen cancer vaccine prime

BIOLOGICAL

GRT-R902

a patient-specific neoantigen cancer vaccine boost

BIOLOGICAL

nivolumab

anti-PD-1 monoclonal antibody

BIOLOGICAL

ipilimumab

anti-CTLA-4 monoclonal antibody

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-13
Primary Completion
2022-11-10
Completion
2022-11-10
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639714 on ClinicalTrials.gov